Genmab A/SGMABNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank14
3Y CAGR-77.0%
5Y CAGR-57.4%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-77.0%/yr
vs +24.4%/yr prior
5Y CAGR
-57.4%/yr
Recent deceleration
Acceleration
-101.4pp
Decelerating
Percentile
P14
Within normal range
vs 5Y Ago
0x
Contraction
Streak
3 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 1.32% |
| 2024 | 14.95% |
| 2023 | 23.21% |
| 2022 | 108.57% |
| 2021 | 94.10% |
| 2020 | 93.27% |
| 2019 | 60.04% |
| 2018 | 45.38% |
| 2017 | 43.52% |
| 2016 | 12.27% |